GEN Exclusives

More »

GEN News Highlights

More »
Sep 6, 2013

Human Urine Metabolome Study Envisions New Diagnostic Era

  • University of Alberta scientists completed a seven-year study that ultimately determined the chemical composition of human urine. The project, which involved a team of nearly 20 investigators using nuclear magnetic resonance spectroscopy, gas chromatography, mass spectrometry, and liquid chromatography, revealed more than 3,000 metabolites can be detected in urine.

    The results are expected to have significant implications for medical, nutritional, drug, and environmental testing, say the researchers.

    “As a biological waste material, urine typically contains metabolic breakdown products from a wide range of foods, drinks, drugs, environmental contaminants, endogenous waste metabolites, and bacterial by-products,” wrote the scientists in this month’s issue of PLOS ONE. “Many of these compounds are poorly characterized and poorly understood. In an effort to improve our understanding of this biofluid we have undertaken a comprehensive, quantitative, metabolome-wide characterization of human urine. This involved both computer-aided literature mining and comprehensive, quantitative experimental assessment/validation.”

    Most medical textbooks list only 50 to 100 chemicals in urine, and most common clinical urine tests measure only six to seven compounds, explained David Wishart, Ph.D, senior scientist on the team. “Expanding the list of known chemicals in urine by a factor of 30 and improving the technology so that we can detect hundreds of urine chemicals at a time could be a real game-changer for medical testing,” he added.

    He believes this study (entitled “The Human Urine Metabolome”) is particularly significant because it will allow an entire new generation of fast, cheap, and painless medical tests to be performed using urine instead of blood or tissue biopsies. In particular, he notes that new urine-based diagnostic tests for colon cancer, prostate cancer, celiac disease, ulcerative colitis, pneumonia, and organ transplant rejection are already being developed or are about to enter the marketplace, thanks in part to this work.



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should “Special K” Get Special Treatment?

In the near term, what is the best way to use ketamine in treating depression?